protocolSection identificationModule nctId: NCT06328036, orgStudyIdInfo id: NCI-2024-02185, secondaryIdInfos id: NCI-2024-02185, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: 10640, type: OTHER, domain: University of Pittsburgh Cancer Institute LAO, secondaryIdInfos id: 10640, type: OTHER, domain: CTEP, secondaryIdInfos id: UM1CA186690, type: NIH, link: https://reporter.nih.gov/quickSearch/UM1CA186690, briefTitle: Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-21, primaryCompletionDateStruct date: 2025-07-01, completionDateStruct date: 2025-07-01, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: National Cancer Institute (NCI), class: NIH, descriptionModule briefSummary: This phase II trial compares the safety, side effects and effectiveness of atezolizumab with tiragolumab to atezolizumab alone in treating patients with glioblastoma that has come back after a period of improvement (recurrent). Glioblastoma is the most common primary brain cancer in adults and despite aggressive treatment, it is nearly always fatal. Currently, there are limited effective treatment options in patients that have recurrence. Immunotherapy has been shown to be effective in other types of cancer and may be an appealing potential treatment option for recurrent glioblastoma. Immunotherapy with monoclonal antibodies, such as atezolizumab and tiragolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Study doctors also want to learn if a tumor infiltrating T lymphocyte (TIL) response is helpful to determine the benefit of the combination of study drugs compared to the usual approach. TILs are a type of immune cell that has moved from the blood into a tumor. TILs can recognize and kill tumor cells. Giving atezolizumab with tiragolumab may be safe, tolerable and/or effective compared to atezolizumab alone in treating patients with recurrent glioblastoma., conditionsModule conditions: Recurrent Glioblastoma, IDH-Wildtype, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 52, type: ESTIMATED, armsInterventionsModule interventions name: Atezolizumab, interventions name: Biospecimen Collection, interventions name: Magnetic Resonance Imaging, interventions name: Surgical Procedure, interventions name: Tiragolumab, outcomesModule primaryOutcomes measure: Progression free survival (PFS), secondaryOutcomes measure: Tumor infiltrating T lymphocyte density, secondaryOutcomes measure: Dose limiting toxicity, secondaryOutcomes measure: Incidence of adverse events, secondaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: PFS6, secondaryOutcomes measure: Overall survival, secondaryOutcomes measure: Tumor mutational burden (TMB), secondaryOutcomes measure: Expression of immune checkpoint receptors and ligands, otherOutcomes measure: Tumor response signatures including for T-cells, interferon and cell cycle, otherOutcomes measure: T cell receptor (TCR) clonality and diversity, otherOutcomes measure: Tumor infiltrating T-cell, T-regs, and myeloid cells, otherOutcomes measure: TCR overlap and clonal expression, otherOutcomes measure: Peripheral blood mononuclear cell (PBMC) response signatures including for T-cells, interferon and cell cycle, otherOutcomes measure: TCR clonality by PBMC, otherOutcomes measure: TCR clonality, otherOutcomes measure: Trough concentrations in serum and concentrations in cerebrospinal fluid, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False